汇禾医疗完成数亿元D轮融资，险资领投

Core Viewpoint - Shanghai Huihe Medical Technology Co., Ltd. has completed its D round financing, led by Taiping Medical Health Fund, marking a significant milestone following its C+ round financing in 2022 [1] Group 1: Financing and Investment - The D round financing was strategically led by Taiping Medical Health Fund, with existing shareholder Suzhou Sherpa II Equity Investment Partnership participating [1] - Insurance capital has become a crucial driving force in the development of the healthcare industry, characterized by long-term stability and cross-cycle allocation, aligning well with the healthcare sector's long cycles and high investments [1] Group 2: Company Strengths and Market Potential - Huihe Medical possesses unique competitive advantages and significant growth potential, excelling in delivery systems, precision manufacturing, simulation, and automated production [2] - The company has developed several world-leading commercial products in the cardiovascular intervention field, including the globally pioneering K-Clip® transcatheter tricuspid valve repair system, which has received approval from the National Medical Products Administration (NMPA) and is undergoing large-scale commercialization [2] - There is a substantial unmet clinical need in the structural heart disease sector, with a 32.5% increase in hospitals treating these patients from 2022 to 2023, and a 38.1% rise in inpatient visits [2] Group 3: Future Outlook and Strategic Goals - Taiping Medical Health Fund emphasizes a research-first approach, focusing on innovative and competitive products, with expectations for Huihe Medical's K-Clip® to become a commercially viable solution globally [3] - The completion of this financing round will provide Huihe Medical with sufficient funding, insurance channels, and medical institution resources to accelerate the promotion and application of K-Clip® in both domestic and international markets [3] - Huihe Medical aims to continue innovating in the cardiovascular intervention field, offering less invasive and safer treatment options while contributing to global healthcare with Chinese wisdom and solutions [3]